In a similar manner, the RCT investigating recombinant human NGF demonstrated a high degree of unblinding related to injection site myalgia, which when accounted for in a separate analysis reported a more attenuated treatment-related difference which consequently lost statistical significance. This evidence concerns the gene NGF and Myalgia.